Palladyne AI Corp. (PDYN)

NASDAQInformation TechnologySoftware - InfrastructureSnapshot 2026-10-23

$3.70+1.37%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Palladyne AI Corp.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	7.99M
EPS	—	-0.195
FY 2026 · Annual
Revenue	$24M–$27M	24.85M
EPS	—	-0.985
FY 2027 · Annual
Revenue	—	40.02M
EPS	—	-0.768

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Free cash flow improves to about $2 million in FY25	The company plans to improve cash flow and net income.	Broken	Free cash flow remains negative or below $1.6 million in FY25	Free cash flow: $-11.024M FY2026-Q2; GAAP. Published target: ~$2 million. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-11,024,000 USD · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Net income improves from -$12.6 million in 2026-Q1	The company plans to improve cash flow and net income.	Broken	Net loss worsens beyond -$12.6 million in next 4 quarters	Net income: $-12.326M FY2026-Q2; GAAP. Published target: Net loss narrows vs -$12.6 million in 2026-Q1. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-12,326,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 2931501a-f019-4618-b641-ea8a04d8d85d. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Expand partnership with Israel Aerospace Industries	It has a strong partnership with Israel Aerospace Industries.	Improving	Partnership stalls or reverses in next 4 quarters	Qualitative: MOU signed 2026-06-08; no stall/reversal reported June 2026 MOU with IAI grants exclusive U.S. rights to manufacture loitering munitions. No subsequent news indicates partnership stall or reversal. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 recent disclosures including 2026-Q2. The partnership with Israel Aerospace Industries grants Palladyne exclusive U.S. rights to manufacture and market combat-proven loitering munitions. This strategic move aligns with management's emphasis on expanding defense capabilities and is supported by the June 2026 announcement and the Q2 2026 report. The trajectory shows active execution of this partnership as a core growth initiative. Delivery assessment Oct 24, 2026
Revenue reaches about $25.5 million in FY26	Palladyne aims to grow revenue to about $25.5 million in 2026.	Improving	Revenue falls below $24 million in FY26	Revenue: $5.783M FY2026-Q2; GAAP. Published target: ~$25.5 million. Target period is not explicitly aligned with this observation. Source published Aug 6, 20265,783,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 2931501a-f019-4618-b641-ea8a04d8d85d. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 recent disclosures including 2026-Q2. The partnership with Israel Aerospace Industries grants Palladyne exclusive U.S. rights to manufacture and market combat-proven loitering munitions. This strategic move aligns with management's emphasis on expanding defense capabilities and is supported by the June 2026 announcement and the Q2 2026 report. The trajectory shows active execution of this partnership as a core growth initiative. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	2 / 3
2026-07-25	Unavailable	Unavailable	2 / 4
2026-07-26	Unavailable	Unavailable	2 / 4
2026-07-27	Unavailable	Unavailable	2 / 4
2026-07-28	Unavailable	Unavailable	2 / 4
2026-07-29	Unavailable	Unavailable	2 / 4
2026-07-30	Unavailable	Unavailable	2 / 4
2026-07-31	Unavailable	Unavailable	2 / 3
2026-08-01	Unavailable	Unavailable	2 / 3
2026-08-02	Unavailable	Unavailable	2 / 4
2026-08-03	Unavailable	Unavailable	2 / 4
2026-08-04	Unavailable	Unavailable	2 / 4
2026-08-05	Unavailable	Unavailable	2 / 4
2026-08-06	Unavailable	Unavailable	2 / 4
2026-08-07	Unavailable	Unavailable	2 / 3
2026-08-08	Unavailable	Unavailable	3 / 4
2026-08-09	Unavailable	Unavailable	2 / 3
2026-08-10	Unavailable	Unavailable	2 / 4
2026-08-12	Unavailable	Unavailable	2 / 3
2026-08-13	Unavailable	Unavailable	2 / 3
2026-08-14	Unavailable	Unavailable	2 / 3
2026-08-15	Unavailable	Unavailable	2 / 3
2026-08-16	Unavailable	Unavailable	2 / 3
2026-08-17	Unavailable	Unavailable	2 / 3
2026-08-18	Unavailable	Unavailable	2 / 3
2026-08-19	Unavailable	Unavailable	2 / 3
2026-08-20	Unavailable	Unavailable	2 / 3
2026-08-21	Unavailable	Unavailable	2 / 3
2026-08-22	Unavailable	Unavailable	2 / 3
2026-08-23	Unavailable	Unavailable	2 / 3
2026-08-24	Unavailable	Unavailable	2 / 3
2026-08-25	Unavailable	Unavailable	2 / 3
2026-08-26	Unavailable	Unavailable	2 / 3
2026-08-27	Unavailable	Unavailable	2 / 3
2026-08-28	Unavailable	Unavailable	2 / 3
2026-08-29	Unavailable	Unavailable	2 / 3
2026-08-30	Unavailable	Unavailable	2 / 3
2026-08-31	Unavailable	Unavailable	2 / 3
2026-09-01	Unavailable	Unavailable	2 / 3
2026-09-02	Unavailable	Unavailable	2 / 3
2026-09-03	Unavailable	Unavailable	2 / 3
2026-09-04	Unavailable	Unavailable	2 / 3
2026-09-05	Unavailable	Unavailable	2 / 3
2026-09-06	Unavailable	Unavailable	2 / 3
2026-09-07	Unavailable	Unavailable	2 / 3
2026-09-08	Unavailable	Unavailable	2 / 3
2026-09-09	Unavailable	Unavailable	2 / 3
2026-09-10	Unavailable	Unavailable	2 / 3
2026-09-11	Unavailable	Unavailable	2 / 3
2026-09-12	Unavailable	Unavailable	2 / 3
2026-09-13	Unavailable	Unavailable	2 / 3
2026-09-14	Unavailable	Unavailable	2 / 3
2026-09-15	Unavailable	Unavailable	2 / 3
2026-09-16	Unavailable	Unavailable	2 / 3
2026-09-17	Unavailable	Unavailable	2 / 3
2026-09-18	Unavailable	Unavailable	2 / 3
2026-09-19	Unavailable	Unavailable	2 / 3
2026-09-20	Unavailable	Unavailable	2 / 3
2026-09-21	Unavailable	Unavailable	2 / 3
2026-09-22	Unavailable	Unavailable	2 / 3
2026-09-23	Unavailable	Unavailable	2 / 3
2026-09-24	Unavailable	Unavailable	2 / 3
2026-09-25	Unavailable	Unavailable	2 / 3
2026-09-26	Unavailable	Unavailable	2 / 3
2026-09-27	Unavailable	Unavailable	2 / 3
2026-09-28	Unavailable	Unavailable	2 / 3
2026-09-29	Unavailable	Unavailable	2 / 3
2026-09-30	Unavailable	Unavailable	2 / 3
2026-10-01	Unavailable	Unavailable	2 / 3
2026-10-02	Unavailable	Unavailable	2 / 3
2026-10-03	Unavailable	Unavailable	2 / 3
2026-10-04	Unavailable	Unavailable	2 / 3
2026-10-05	Unavailable	Unavailable	2 / 3
2026-10-06	Unavailable	Unavailable	2 / 3
2026-10-07	Unavailable	Unavailable	2 / 3
2026-10-08	Unavailable	Unavailable	2 / 3
2026-10-09	Unavailable	Unavailable	2 / 3
2026-10-10	Unavailable	Unavailable	2 / 3
2026-10-11	Unavailable	Unavailable	2 / 3
2026-10-12	Unavailable	Unavailable	2 / 3
2026-10-13	Unavailable	Unavailable	2 / 3
2026-10-14	Unavailable	Unavailable	2 / 3
2026-10-15	Unavailable	Unavailable	2 / 3
2026-10-16	Unavailable	Unavailable	2 / 3
2026-10-17	Unavailable	Unavailable	2 / 3
2026-10-18	Unavailable	Unavailable	2 / 3
2026-10-19	Unavailable	Unavailable	2 / 3
2026-10-20	Unavailable	Unavailable	2 / 3
2026-10-21	Unavailable	Unavailable	2 / 3
2026-10-22	Unavailable	Unavailable	2 / 3
2026-10-23	Unavailable	Unavailable	2 / 3
2026-10-24	Unavailable	Unavailable	2 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	3	1
2026-06-01	3	1
2026-07-01	3	1
2026-08-01	3	1
2026-09-01	3	1
2026-10-01	3	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Free cash flow improves to about $2 million in FY25Published status: Broken
Net income improves from -$12.6 million in 2026-Q1Published status: Broken
Revenue reaches about $25.5 million in FY26Revenue: $5.783M

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.2%Typical daily move · historical

Downside history

-63.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Palladyne AI Corp. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

PDYN is a speculative growth company rather than an established compounder, with a loss-making business and high risk. Its long-term thesis is in a watch state: recent momentum improved, but financial performance remains weak and the company has recorded consecutive earnings misses.

What's priced into Palladyne AI Corp.

PDYN trades at a substantial premium to peers, and the valuation model has low confidence. The expectations gap is negative, suggesting expectations may be ahead of the evidence; the priced-in assessment calls the premium justified, but that view rests mainly on future growth potential.

What the fundamentals likely do

Near term, revenue has grown sequentially, and management reaffirmed its 2026 revenue guidance of $24 million to $27 million. Operating cash burn rose from about $8.5 million in the first quarter to about $10.2 million in the second, so delivering lower burn in the second half is an important test. The next earnings report carries added risk after recent misses, while progress on the Israel Aerospace Industries partnership is mixed.

What Palladyne AI Corp. hinges on

The multi-year view depends on converting backlog into revenue, meeting 2026 guidance, and making the defense partnership a meaningful growth initiative. A guidance cut would weaken the thesis, while lower interest rates or continued strong results from major technology companies could support the sector backdrop. Those broader factors do not resolve PDYN’s company-specific execution and cash-burn risks.